Historically, atopic dermatitis (AD) has been treated with topical corticosteroids and topical calcineurin inhibitors. Even with their efficacy and infrequent adverse events, fear has limited their use. Therefore, more options are needed.
Phosphodiesterase 4 (PDE4) inhibitors studied as an alternative treatment option appear promising for children and adults.
Access the article at the Journal of the American Academy of Dermatology. (Requires subscription to view the full article.)
Work Cited:
Phosphodiesterase 4 inhibitors, Zebda, Rema et al., Journal of the American Academy of Dermatology, Volume 78, Issue 3, S43 – S52